Table 1.

Demographics, treatment, and clinical outcomes

	Entire UPS cohort	Discovery cohort	Expansion cohort
	N = 15	N = 10	N = 5
Follow-up months (range, SD)	20.2 (4–46, 12)	20.5 (4–46; 12.1)	19.6 (12–43; 13.1)
Lost to follow-up	0	0	0
Female	6 (40%)	4 (40%)	2 (40%)
Age (range, SD)	69.5 (48–85; 9.6)	69.3 (48–85;11.3)	70 (62–76; 6)
Stage
II	4 (26.7%)	3 (30%)	1 (20%)
III	8 (53.3%)	4 (40%)	4 (80%)
IV	3 (20%)	3 (30%)
Tumor size cm (range, SD)	9.8 (3–34; 8.1)	8.8 (3–21.5, 5.6)	11.7 (3–34; 12.5)
Deep	10 (66.7%)	6 (60%)	4 (80%)
Grade 3	14 (93.3%)	9 (90%)	5 (100%)
Received neoadjuvant chemotherapy	1 (6.7%)	1 (10%)	0 (0%)
Received neoadjuvant radiation	1 (6.7%)	1 (10%)	0 (0%)
Adjuvant radiation	13 (86.7%)	9 (90%)	4 (80%)
(IORT or EBRT)
Local recurrence	1 (6.7%)	0	1 (20%)
Metastatic recurrence	3 (20%)	2 (20%)	1 (20%)
Current status
NED	10 (66.7%)	8 (80%)	2 (40%)
AWD	2 (13.3%)	0	2 (40%)
DOD	2 (13.3%)	2 (20%)	0
DWD	1 (6.7%)	0	1 (20%)